- Home
- ACIU vs NEWT Comparison
ACIU vs NEWT Comparison
Compare ACIU & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- NEWT
- Stock Information
- Founded
- ACIU 2003
- NEWT 1998
- Country
- ACIU Switzerland
- NEWT United States
- Employees
- ACIU N/A
- NEWT N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- NEWT Major Banks
- Sector
- ACIU Health Care
- NEWT Finance
- Exchange
- ACIU Nasdaq
- NEWT Nasdaq
- Market Cap
- ACIU 305.7M
- NEWT 365.7M
- IPO Year
- ACIU 2016
- NEWT N/A
- Fundamental
- Price
- ACIU $3.27
- NEWT $14.02
- Analyst Decision
- ACIU Strong Buy
- NEWT Hold
- Analyst Count
- ACIU 2
- NEWT 3
- Target Price
- ACIU $12.00
- NEWT $14.33
- AVG Volume (30 Days)
- ACIU 131.4K
- NEWT 158.0K
- Earning Date
- ACIU 11-05-2024
- NEWT 11-06-2024
- Dividend Yield
- ACIU N/A
- NEWT 5.50%
- EPS Growth
- ACIU N/A
- NEWT 22.62
- EPS
- ACIU N/A
- NEWT 1.68
- Revenue
- ACIU $48,505,404.00
- NEWT $316,405,000.00
- Revenue This Year
- ACIU N/A
- NEWT N/A
- Revenue Next Year
- ACIU $938.44
- NEWT $6.55
- P/E Ratio
- ACIU N/A
- NEWT $8.21
- Revenue Growth
- ACIU 4097200.00
- NEWT 38.64
- 52 Week Low
- ACIU $2.25
- NEWT $10.07
- 52 Week High
- ACIU $5.14
- NEWT $15.49
- Technical
- Relative Strength Index (RSI)
- ACIU 54.88
- NEWT 52.22
- Support Level
- ACIU $3.11
- NEWT $13.48
- Resistance Level
- ACIU $3.41
- NEWT $13.95
- Average True Range (ATR)
- ACIU 0.23
- NEWT 0.58
- MACD
- ACIU 0.03
- NEWT -0.09
- Stochastic Oscillator
- ACIU 46.72
- NEWT 39.47
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions, It has developed a financial and technology-based business model that enables itself to acquire and process its clients in a very cost-effective manner. This capability is supported in large part by NewTracker, its patented prospect management technology software, that will allow NewtekOne clients to easily interact with NewtekOne subject matter experts in the areas of Banking, Lending, Payments, Technology, Payroll, and Insurance. It offers NewtekOne's clients a single online dashboard to access all of NewtekOne's business and financial solutions. It has four reportable segments Banking, Technology, NSBF, and Payments.